During the last session, ImmunoPrecise Antibodies Ltd (NASDAQ:IPA)’s traded shares were 0.37 million, with the beta value of the company hitting 0.27. At the end of the trading day, the stock’s price was $0.42, reflecting an intraday loss of -12.47% or -$0.06. The 52-week high for the IPA share is $2.60, that puts it down -519.05 from that peak though still a striking -4.76% loss since the share price plummeted to a 52-week low of $0.44. The company’s market capitalization is $11.66M, and the average intraday trading volume over the past 10 days was 1.74 million shares, and the average trade volume was 442.25K shares over the past three months.
ImmunoPrecise Antibodies Ltd (NASDAQ:IPA) trade information
ImmunoPrecise Antibodies Ltd (IPA) registered a -12.47% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -12.47% in intraday trading to $0.42, hitting a weekly high. The stock’s 5-day price performance is -38.43%, and it has moved by -23.04% in 30 days. Based on these gigs, the overall price performance for the year is -80.31%. The short interest in ImmunoPrecise Antibodies Ltd (NASDAQ:IPA) is 0.15 million shares and it means that shorts have 0.45 day(s) to cover.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ImmunoPrecise Antibodies Ltd (IPA) estimates and forecasts
Statistics show that ImmunoPrecise Antibodies Ltd has outperformed its competitors in share price, compared to the industry in which it operates. ImmunoPrecise Antibodies Ltd (IPA) shares have gone down -67.38% during the last six months, with a year-to-date growth rate more than the industry average at 61.54% against 24.40. In the rating firms’ projections, revenue will increase 0.30% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 4.62M as predicted by 2 analyst(s). Meanwhile, a consensus of 2 analyst(s) estimates revenue growth to 4.81M by the end of current fiscal year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -11.23%. While earnings are projected to return 55.45% in 2024.
IPA Dividends
ImmunoPrecise Antibodies Ltd is due to release its next quarterly earnings on 2024-Dec-12. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
ImmunoPrecise Antibodies Ltd (NASDAQ:IPA)’s Major holders
ImmunoPrecise Antibodies Ltd insiders own 12.06% of total outstanding shares while institutional holders control 5.75%, with the float percentage being 6.53%. INGALLS & SNYDER LLC is the largest shareholder of the company, while 21.0 institutions own stock in it. As of 2024-06-30, the company held over 1.3 million shares (or 5.0209% of all shares), a total value of $1.31 million in shares.
The next largest institutional holding, with 63910.0 shares, is of RENAISSANCE TECHNOLOGIES LLC’s that is approximately 0.2477% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $64549.0.
